Conducting national burden of disease studies in small countries in Europe– a feasible challenge?

• Published in: Archives of Public Health
• Main Authors: Cuschieri, Sarah, Pallari, Elena, Terzic, Natasa, Alkerwi, Ala’a, Sigurvinsdottir, Rannveig, Sigfusdottir, Inga Dora, Devleesschauwer, Brecht
• Format: Text
• Language: English
• Published: BioMed Central 2021
• Subjects: Commentary; Iceland
• Online Access: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112005/; http://www.ncbi.nlm.nih.gov/pubmed/33971960; https://doi.org/10.1186/s13690-021-00599-z

BACKGROUND: Burden of Disease (BoD) studies use disability-adjusted life years (DALYs) as a population health metric to quantify the years of life lost due to morbidity and premature mortality for diseases, injuries and risk factors occurring in a region or a country. Small countries usually face a number of challenges to conduct epidemiological studies, such as national BoD studies, due to the lack of specific expertise and resources or absence of adequate data. Considering Europe’s small countries of Cyprus, Iceland, Luxembourg, Malta and Montenegro, the aim was to assess whether the various national data sources identified are appropriate to perform national BoD studies. MAIN BODY: The five small countries have a well-established mortality registers following the ICD10 classification, which makes calculation of years of life lost (YLL) feasible. A number of health information data sources were identified in each country, which can provide prevalence data for the calculation of years lived with disability (YLD) for various conditions. These sources include disease-specific registers, hospital discharge data, primary health care data and epidemiological studies, provided by different organisations such as health directorates, institutes of public health, statistical offices and other bodies. Hence, DALYs can be estimated at a national level through the combination of the YLL and YLD information. On the other hand, small countries face unique challenges such as difficulty to ensure sample representativeness, variations in prevalence estimates especially for rarer diseases, existence of a substantial proportion of non-residents affiliated to healthcare systems and potential exclusion from some European or international initiatives. Recently established BoD networks may provide a platform for small countries to share experiences, expertise, and engage with countries and institutions that have long-standing experience with BoD assessment. CONCLUSION: Apart from mortality registries, adequate health data sources, ...